Abstract:Dysregulated cell division, which leads to aberrant cell proliferation, is one of the key hallmarks of cancer. Therefore, therapeutic targets that block cell division would be effective for cancer treatment. Cell division is mainly controlled by a complex composed of cyclin and cyclin dependent kinases (CDKs). To date, the CDK inhibitors (CDKIs), specifically the ones that block the enzyme activity of CDK4 and CDK6 (CDK4/6), have been approved by FDA for the treatment of metastatic hormone receptor positive breast cancer. However, due to the non-selectivity and significant toxicity, most of the first generation CDK inhibitors (so called pan-CDK inhibitors that target several CDKs), have not been approved for clinical application. Despite this, great efforts and progress have been made to enable pan-CDK inhibitors application in the clinical setting. Notably, the development of combination therapy strategies in recent years has made it possible to reduce the toxicity and side effects of pan-CDK inhibitors. Thus, as a combination therapy approach, pan-CDK inhibitors regain great potential in clinical application. In this review, we introduced the CDK family members and discussed their major functions in cell cycle controlling. Then, we summarized the research progress regarding CDK inhibitors, especially those other than CDK4/6 inhibitors. We reviewed first-generation pan-CDKIs Flavopiridol and Roscovitine, and second-generation CDKIs Dinaciclib, P276-00, AT7519, TG02, Roniciclib, RGB-286638 by focusing on their developing stages, clinical trials and targeting cancers. The specific CDKIs, which targets to increase specificity and decrease the side effects, were also discussed. These CDKIs include CDK4/6, CDK7, CDK9, and CDK12/13 inhibitors. Finally, the efficacy and discrepancy of combination therapy with CDK inhibitors and PD1/PDL1 antibodies were analyzed, which might give insights into the development of promising strategy for cancer treatment.

Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy

Small-molecule degraders of cyclin-dependent kinase protein: a review

Discovery of small molecule degraders for modulating cell cycle

Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.

CDK inhibitors in cancer therapy, an overview of recent development

Cyclin Dependent Kinase 1 Inhibitors: a Review of Recent Progress.

Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs

Targeting CDK9 in Cancer: An Integrated Approach of Combining In Silico Screening with Experimental Validation for Novel Degraders

Development of Degraders of Cyclin-Dependent Kinases 4 and 6 Based on Rational Drug Design

Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy

Recent Progress in CDK4/6 Inhibitors and PROTACs

Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells

Targeting CDK9 with Selective Inhibitors or Degraders in Tumor Therapy: an Overview of Recent Developments

Development of CDK2 and CDK5 Dual Degrader TMX‐2172

Novel Medicinal Chemistry Strategies Targeting CDK5 for Drug Discovery

Development of Selective Mono or Dual PROTAC Degrader Probe of CDK Isoforms.

Inhibitors and PROTACs of CDK2: challenges and opportunities

Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.

Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy

Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors

Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment.